Skip Navigation

Rheumatology 2008 47(Supplement 5):v62-v64; doi:10.1093/rheumatology/ken272
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Silver, R. M.
Right arrow Articles by Wells, A. U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silver, R. M.
Right arrow Articles by Wells, A. U.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

This article appears in the following Rheumatology issue: Update in systemic sclerosis [View the issue table of contents]

Histopathology and bronchoalveolar lavage

R. M. Silver1 and A. U. Wells2

1Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA and 2Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.

Correspondence to: R. M. Silver, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston SC 29425, USA. E-mail: silverr{at}musc.edu


   Abstract

Although neither lung biopsy nor bronchoalveolar lavage (BAL) is recommended for routine clinical use in patients with SSc, studies employing lung biopsy material and BAL fluid (BALF) have provided insight into the pathogenesis of scleroderma-associated interstitial lung disease (SSc-ILD). Most often, SSc-ILD is classified as a non-specific interstitial pneumonia, with abundant myofibroblasts and evidence of both epithelial cell and endothelial cell injury. Recently, SSc-ILD fibroblasts have been shown to express reduced levels of the caveolin-1 protein which, in turn, may lead to activation of the signalling molecules associated with increased collagen production and overexpression of {alpha}-smooth muscle cell actin ({alpha}-SMA). BALF often contains increased numbers of inflammatory cells as well as myofibroblasts expressing {alpha}-SMA. Analysis of BALF suggests an imbalance between pro-fibrotic and anti-fibrotic factors, e.g. an overabundance of TGF-β, connective tissue growth factor (CTGF), PDGF, leucotriene B4, etc. and in some cases a deficiency of hepatocyte growth factor, 15-hydroxyeicosatetraenoic acid (15-HETE), lipoxin A, etc. Until the pathogenesis is fully understood, lung biopsy and BAL will remain useful research tools to better understand the inflammatory and fibrosing processes that underlie SSc-ILD.

KEY WORDS: Scleroderma, Interstitial lung disease, Lung biopsy, Lung histopathology, Myofibroblast, Bronchoalveolar lavage, Cytokines, Growth factors

Submitted 1 May 2008; Accepted 18 June 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.